Peer-reviewed veterinary case report
Safety of doxorubicin and toceranib chemo in dogs with tumors
By Pellin, M A et al.·Published in Veterinary and comparative oncology·2017·Department of Medical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.
- Species:
- dog
Plain-English summary
A group of dogs with tumors received a combination of two chemotherapy drugs, doxorubicin and toceranib (Palladia), to see how well they could tolerate it and if it would help fight their cancer. The study found that the dogs could safely receive a specific dose of doxorubicin alongside toceranib without experiencing severe side effects, such as gastrointestinal issues. Most dogs showed positive responses to the treatment, indicating that this combination could be effective against tumors. Further studies are planned to explore its long-term effects and effectiveness.
People also search for: dog cancer treatment doxorubicin toceranib · side effects of Palladia in dogs · combination chemotherapy for dog tumors
Abstract
Combination chemotherapy holds promise for improving outcomes in malignancy when compared with single-agent approaches. Care must be taken to avoid overlapping toxicity and to utilize agents with differing mechanisms of action. A phase I dose-finding trial was performed to determine the maximally tolerated dose (MTD) of a concurrent toceranib and doxorubicin (DOX) combination protocol where toceranib dose was maintained at or near 2.75 mg kgby mouth every other day (PO EOD) while escalating DOX dosage. The dose-limiting toxicity was found to be neutropenia and the MTD of the combination was determined to be 25 mg mof DOX q 21 days given concurrently with toceranib 2.75 mg kgPO EOD. This combination was well tolerated with no excessive gastrointestinal toxicity nor novel adverse events (AEs) noted. Anti-tumour activity was observed in the majority of cases. This combination warrants further investigation in the context of phase II/III clinical trials to characterize efficacy and long-term AE profiles.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27146577/